News & Events

• November 3, 2011
  

  Capturing the Signal in Mild Cognitive Impairment of the Alzheimer’s Type: Industry Partnerships in Pre-Competitive Measure Development

• November 3, 2011
  

  Mixing Modes of Patient-Reported Outcomes Data Collection in Clinical Trials: Recommendations

• November 1, 2011
  

  Measuring the Earliest Symptoms of Mild Cognitive Impairment

• November 1, 2011
  

  C-Path Joins Leading Voices and Organizations in Alzheimer’s Research, Drug Discovery and Care to Call for Dramatic New Strategy to Stop Alzheimer’s Disease in Report Out Today

  Leaders Engaged on Alzheimer’s Disease (LEAD) was created in February 2008 as an open network of Alzheimer’s-serving organizations to link key stakeholders from the government, business, and civic sectors to increase attention to and awareness of Alzheimer’s disease, its care, treatment, prevention, research, and eventual cure.
• October 28, 2011
  

  C-Path’s Avilés Discusses Importance of Data Standards in FDA Week Article

  FDA is encouraging industry to use newly crafted therapeutic data standards — such as utilization of qualified biomarkers– in submissions and could start requiring companies to use the standardized data elements in the future,sources said following the release of the first set of standardized therapeutic data elements for Alzheimer’s disease that they said could make...